Cervical Pain, Pain
Conditions
Brief summary
Myofascial pain syndrome (MPS) is a musculoskeletal disorder which is characterized by pain, muscle spasms and muscle tenderness, as well as a limited range of motion, weakness, and rarely, autonomous dysfunction.
Detailed description
The occurrences of morbidity of the neck after cancer therapy were considerable and consisted of neck pain, loss of sensation, and decreased range of motion. Extracorporeal shock wave therapy (ESWT) is one of the treatment options used for patients with myofascial pain syndrome through elimination of ischemia and modulation of vasoneuroactive substance (two major causes of trigger pathophysiology) and mechanical transduction as a cellular response to external stimulation. the aim of this study was to investigate efficacy of extracorporeal shock wave therapy (ESWT) on cervical myofascial pain following neck dissection surgery.
Interventions
DEVICEextra-corporeal shock wave therapy
Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
DRUGtopical none steroidal anti-inflammatory drug
participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
Sponsors
Cairo University
Qassim University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Previous unilateral modified radical neck dissection. 2. Patients with myofascial pain of upper trapezius for at least 3 months. 3. Patients with palpable intramuscular taut band. 4. Restriction in cervical ROM of lateral flexion and rotation. 5. Provocation of the clinical symptoms by compression of the active trigger point
Exclusion criteria
1. Patient who received medication or other therapies for MPS within the previous 2 months. 2. Patients with pacemaker, pregnancy 3. Open wound at the treatment area. 4. Cervical myelopathy or radiculopathy, cervical spine fracture or spondylolisthesis. 5. Rheumatoid arthritis. 6. Coagulopathy. 7. Epilepsy or any psychological disorder.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual analogue scale | before treatment | VAS was utilized for assessing and quantifying pain exhibited by the patients through a 0-10 cm scale. Each subject was informed to mark the line according to the pain intensity experienced at that particular time where '0' means no pain and '10' means worst conceivable pain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cervical range of motion assessment | before treatment | Cervical range of motion device (CROM; Performance Attainment Associates) was used for assessment of neck lateral flexion and rotation of both sides. The CROM instrument contains a plastic frame put on the head above the nose and ears, attached at the head back by a Velcro strap to allow precise measure, re-measure and rotational motion in an upright place to avoid individual errors. Two independent inclinometers are connected to the frame and point the head position in relation to the gravity line. Another inclinometer indicates the head position in rotation in relation to a reference position. |
Countries
Egypt
Outcome results
None listed